Γ

SynBioBeta Speaker

Samuel Levin

Neion Bio

Co-Founder & CTO

Sam Levin is a biotech entrepreneur and accomplished scientific leader with 15 years of research experience and over a decade of leading complex, multidisciplinary scientific enterprises. He has deep expertise at the intersection of genetic engineering, automation, and complex systems biology. He has numerous peer-reviewed publications in leading journals and serves as an advisor to multiple companies and research organizations. His work has been featured in top outlets including The New York Times, Forbes, and the Discovery Channel. Prior to Neion Bio, Sam was the Co-Founder and CEO of Melonfrost, where he built the world’s most high-throughput automated bioreactor system, integrated with proprietary machine learning algorithms to direct microbial evolution for industrial biotechnology. Sam holds a PhD and Bachelor’s Degree in the field of evolutionary biology from the University of Oxford.

Sessions Featuring

Samuel

This Year

Spotlight Talk

9:30 AM

-

9:40 AM

Human Health

A 200 Million-Year-Old Bioreactor

As artificial intelligence dramatically accelerates the design of proteins, manufacturing has become a critical bottleneck for medical breakthroughs reaching patients. The infrastructure for producing biologics has remained largely unchanged for over fifty years, and is capital-intensive, slow to scale, and dependent on fragile supply chains. Neion Bio is replacing nearly every component of this infrastructure, from bioreactors to cell culture media, with nature’s most prolific protein factory: the chicken egg. Enabled by breakthroughs in genome engineering and stem cell technology, Neion creates genetically engineered chickens that lay eggs filled with medicines. As a result, they produce life-saving therapeutics at the cost of egg production, eliminate scale-up risk with simple breeding programs, and solve the problem of resiliency by running on grain and water. A small Neion farm can produce the global supply of essential medicines, and can be set up nearly anywhere in the world. 

Spotlight Talk

9:30 AM

-

9:40 AM

Human Health

A 200 Million-Year-Old Bioreactor

As artificial intelligence dramatically accelerates the design of proteins, manufacturing has become a critical bottleneck for medical breakthroughs reaching patients. The infrastructure for producing biologics has remained largely unchanged for over fifty years, and is capital-intensive, slow to scale, and dependent on fragile supply chains. Neion Bio is replacing nearly every component of this infrastructure, from bioreactors to cell culture media, with nature’s most prolific protein factory: the chicken egg. Enabled by breakthroughs in genome engineering and stem cell technology, Neion creates genetically engineered chickens that lay eggs filled with medicines. As a result, they produce life-saving therapeutics at the cost of egg production, eliminate scale-up risk with simple breeding programs, and solve the problem of resiliency by running on grain and water. A small Neion farm can produce the global supply of essential medicines, and can be set up nearly anywhere in the world. 

TBD

Session lineup still growing

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Featuring

Speaker Coming Soon

Previous Speakers Include